

1 **Kinetics and persistence of the cellular and humoral immune**
2 **responses to BNT162b2 mRNA vaccine in SARS-CoV-2-naive and -**
3 **experienced subjects**

4
5 Salomé Desmecht^{1,2¶}, Aleksandr Tashkeev^{1¶}, Nicole Marechal³, H el ene Per ee¹,
6 Yumie Tokunaga¹, Celine Fombellida Lopez^{2,3}, Barbara Polese⁴, C eline Legrand⁴,
7 Marie W ery¹, Myriam Mni¹, Nicolas Fouillien¹, Fran oise Toussaint⁷, Laurent Gillet⁵,
8 Fabrice Bureau⁴, Laurence Lutteri⁶, Marie-Pierre Hayette⁷, Michel Moutschen^{2,3},
9 Christelle Meuris³, Daniel Desmecht^{8&}, Souad Rahmouni^{1&}, Gilles Darcis^{2,3&}

10
11 1: Laboratory of Animal Genomics, GIGA-Medical Genomics. GIGA-Institute.
12 University of Liege, 4000 Liege, Belgium.

13 2: Laboratory of Infectious Diseases, GIGA-I3, GIGA-Institute. University of Liege,
14 4000 Liege, Belgium.

15 3: Department of Infectious Diseases, Li ege University Hospital, 4000 Li ege,
16 Belgium.

17 4: Laboratory of Cellular and Molecular Immunology, GIGA-I3, GIGA Institute,
18 University of Li ege, 4000 Li ege, Belgium.

19 5: Immunology-Vaccinology Laboratory, Department of Infectious and Parasitic
20 Diseases, FARAH, University of Li ege, 4000 Li ege, Belgium.

21 6: Clinical Chemistry Department, University Hospital of Li ege, Li ege, Belgium.

22 7: Department of Clinical Microbiology, University Hospital of Liege, 4000 Liege,
23 Belgium.

24 8: Department of Animal Pathology, FARAH, Li ege University, 4000 Li ege, Belgium.

25
26 Corresponding authors:

27 E-mail : srahmouni@uliege.be

28 E-mail : gddarcis@chuliege.be

29
30 ¶These authors contributed equally to this work

31 &These authors also contributed equally to this work

32
33

34 **Abstract**

35 **Background:** Understanding and measuring the individual level of immune
36 protection and its persistence at both humoral and cellular levels after SARS-CoV-2
37 vaccination is mandatory for the management of the vaccination booster campaign.
38 Our prospective study was designed to assess the immunogenicity of the BNT162b2
39 mRNA vaccine in triggering the humoral and the cellular immune response in
40 healthcare workers up to 6 months after two doses vaccination.

41 **Methods:** This prospective study enrolled 208 healthcare workers from the Liège
42 University Hospital (CHU) of Liège in Belgium. All participants received two doses of
43 BioNTech/Pfizer COVID-19 vaccine (BNT162b2). Fifty participants were SARS-CoV-
44 2 experienced (self-reported SARS-CoV-2 infection) and 158 were naïve (no
45 reported SARS-CoV-2 infection) before the vaccination. Blood sampling was
46 performed at the day of the first (T0) and second (T1) vaccine doses administration,
47 then at 2 weeks (T2), 4 weeks (T3) and 6 months (T4) after the 1st vaccine dose
48 administration. A total of 1024 blood samples were collected. All samples were
49 tested for the presence of anti-Spike antibodies using DiaSorin LIAISON SARS-CoV-
50 2 TrimericS IgG assay. Neutralizing antibodies against the SARS-CoV-2 Wuhan-like
51 variant strain were quantified in all samples using a Vero E6 cell-based
52 neutralization-based assay. Cell-mediated immune response was evaluated at T4 on
53 80 participants by measuring the secretion of IFN- γ on peripheral blood lymphocytes
54 using the QuantiFERON Human IFN- γ SARS-CoV-2, Qiagen. All participants were
55 monitored on weekly-basis for the novo SARS-COV-2 infection for 4 weeks after the
56 1st vaccine dose administration. We analyzed separately the naïve and experienced
57 participants.

58 **Findings:** We found that anti-spike antibodies and neutralization capacity levels were
59 significantly higher in SARS-CoV-2 experienced healthcare workers (HCWs)
60 compared to naïve HCWs at all time points analyzed. Cellular immune response was
61 similar in the two groups six months following 2nd dose of the vaccine. Reassuringly,
62 most participants had a detectable cellular immune response to SARS-CoV-2 six
63 months after vaccination. Besides the impact of SARS-CoV-2 infection history on
64 immune response to BNT162b2 mRNA vaccine, we observed a significant negative
65 correlation between age and persistence of humoral response. Cellular immune

66 response was, however, not significantly correlated to age, although a trend towards
67 a negative impact of age was observed.

68 **Conclusions:** Our data strengthen previous findings demonstrating that
69 immunization through vaccination combined with natural infection is better than 2
70 vaccine doses immunization or natural infection alone. It may have implications for
71 personalizing mRNA vaccination regimens used to prevent severe COVID-19 and
72 reduce the impact of the pandemic on the healthcare system. More specifically, it
73 may help prioritizing vaccination, including for the deployment of booster doses.

74

75

76 Introduction

77 Mass vaccination of the population plays a crucial role in the control of the
78 coronavirus disease 2019 (COVID-19) pandemic. Pioneering studies have shown
79 that the BNT162b2 (Pfizer–BioNTech), as well as the mRNA-1273 (Moderna)
80 vaccines provide strong protective efficacy against COVID-19 in subjects of 16 years
81 old and older (1)(2). Both mRNA vaccines are highly effective in the first few weeks
82 after vaccination against documented infection and symptomatic COVID-19 among
83 adolescents (3)(4). BNT162b2 was proven to be efficient in children younger than 12
84 years of age (5). As for the mRNA-1273, the clinical trial is still ongoing (Clinical Trial:
85 NCT04796896). Such protection is critical as school-age children may play an
86 important role in the transmission of SARS-CoV-2 (6)(7).

87 Nevertheless, several studies indicate that immunity gradually waned in all age
88 groups a few months after having received the second dose of vaccine
89 (8)(9)(10)(11). Indeed, 8 months after COVID-19 mRNA vaccination, the median live-
90 virus neutralizing antibody titer, pseudovirus neutralizing antibody titer, and RBD-
91 specific binding antibody titer elicited by the vaccine are significantly lower than the
92 peak titers (12). As a consequence, the rate of confirmed infection among persons
93 vaccinated revealed a substantial increase as the time from vaccination increased
94 (8)(9)(10)(11). Though, COVID-19 mRNA vaccines-induced protection against
95 hospitalization and death persisted with barely any waning for 6 months after the
96 second dose (8)(9)(10)(11), suggesting that persisting cellular immunity drives the
97 immune response and prevents viral dissemination when antibodies disappear. T cell
98 responses persist up to 6 months after vaccination, with the maintenance of a pool of
99 polyfunctional memory antigen-specific T cells (13)(14). mRNA vaccines also
100 produce persisting functional memory B cells (14).

101 Although the efficacy of the vaccine against severe disease, hospitalization, and
102 death remains high, weakening immunity and emergence of variants of concern
103 create a need for a third vaccine dose (15). Indeed, a very recent study
104 demonstrated that such booster vaccination induces neutralizing immunity even
105 against the new SARS-CoV-2 Omicron harboring 34 mutations more than all the
106 other variants (16). Additional studies has demonstrated a rapid and consistent
107 reduction in the COVID-19 burden among persons living in long-term care facilities
108 after the initiation of a BNT162b2 booster campaign (17) as well as in other groups of

109 age (18). However, information on how pre-existing immunity to SARS-CoV-2 would
110 be boosted by mRNA vaccination remains poorly understood. In particular, the
111 helpfulness and the timing of booster vaccine doses remain to be determined as well
112 as the impact of recovery after SARS-CoV-2 infection. Here, we analyzed the kinetic
113 of humoral response up to 6 months after BNT162b2. We also analyzed cellular
114 response to BNT162b2 6 months after the vaccination. In particular, we studied the
115 impact of previous SARS-CoV-2 infection on immune persistence. All participants
116 were monitored on weekly-based for the novo SARS-CoV-2 infection that may impact
117 immune persistence.

118 **Methods**

119 **Participant Enrollment and blood sampling**

120 Hospital staff members (including health care workers and administrative staff) of
121 CHU of Liège were invited to participate in the study. Participants were enrolled
122 during February 2021. All participants received two doses of 0.3 mL of BNT162b2
123 mRNA vaccine administered to the deltoid muscle with a recommended dose interval
124 of 18-21 days. Demographics and clinical data were collected through a
125 questionnaire and included, among others, information regarding previous SARS-
126 CoV-2 infection. All enrolled participants were over 18 years of age. They all
127 acknowledged that they had understood the study protocol and signed the informed
128 consent. Participants were classified into two groups : “experienced group”, that
129 includes participants with reported SARS-CoV-2 infection prior to vaccination, and
130 “naïve group”, consisting of individuals without previous SARS-CoV-2 infection.
131 Blood was collected at the day of the 1st vaccine dose (T0), the day of second
132 vaccine dose (T1), then and at 14 days (T2), one month (T3) and six months (T4)
133 following the second vaccine dose. A total of about 40ml of blood was collected from
134 each subject at each timepoint.

135 The protocol was approved by the ethics committee (full name: comité d'éthique
136 hospitalo-facultaire universitaire de Liège) of Liège University Hospital (approval
137 number 2021-54).

138 **Cell mediated immune response to SARS-CoV-2 infection**

139 Cell mediated immune response was assessed by measuring the secretion of IFN- γ
140 by peripheral blood lymphocytes using the QuantiFERON Human SARS-CoV-2
141 (Qiagen, Cat. No. / ID: 626410). Briefly, blood was collected on four tubes: the
142 control set including one positive and negative one negative tube and the two original
143 Vacutainer tubes containing SARS- CoV-2 antigen 1 (Ag1) and SARS-CoV-2 antigen
144 2 (Ag2) formulated to activate CD4 T (by Ag1) and both CD4 T and CD8 T (by Ag2)
145 lymphocytes in heparinized whole blood. After blood collection and mixing, tubes
146 were incubated at 37°C for 16 to 24h, IFN- γ was then measured on plasma from the
147 stimulated samples using an CLIA based assay. The threshold for positivity was 0.15
148 IU/mL as given by Qiagen.

149 **SARS-CoV-2 detection**

150 Participants were all invited to perform a weekly saliva self-sampling to detect the
151 presence of SARS-CoV-2 following the instruction provided in the starting pack.
152 Participants were asked to return the samples within 12 hours after sampling to the
153 core facility to perform the required follow-up PCR testing. Results were available to
154 them within 24h on the ULiège online platform: [https://test-
155 covid.uliege.be/testcovid/index_xt.do](https://test-covid.uliege.be/testcovid/index_xt.do).

157 **Assessment of neutralizing antibodies by sero-neutralization 158 testing (SNT)**

159 SNT analysis were conducted in a specialized biosafety level 3 (BSL3) facility using a
160 SARS-CoV-2 virus Wuhan-like variant (BetaCov/Belgium/Sart-Tilman/2020/1)
161 isolated from a patient hospitalized in March 2020. Virus isolation, expansion, titration
162 and SNT analysis were all performed using nonadherent sub-confluent Vero E6 cells
163 (ATCC® CRL-1586) grown in DMEM supplemented with 2% FBS and penicillin-
164 streptomycin.

165 The virus stock was titrated in serial log dilutions to obtain a 50% tissue culture
166 infective dose (TCID50) on 96-well culture plates. The plates were observed daily
167 using inverted optical microscope for five days to evaluate the presence of cytopathic
168 effect (CPE) and the end-point titer was calculated according to the Reed & Muench
169 method based on 2 x 3 replicates.

170 Serum test samples were heat-inactivated for 40 min at 56 °C and two-fold serial
171 dilutions, starting from 1:10 up to 1:320, were performed in triplicate in DMEM/FBS
172 on 96-well culture plates. Sera dilutions (50 µl/well) were then mixed with an equal
173 volume of a pre-titrated viral solution containing 100 TCID₅₀ of SARS-CoV-2 virus.
174 The serum-virus mixture was incubated 1 h at 37 °C in a humidified atmosphere with
175 5% CO₂. After incubation, 100 µl of a Vero cells suspension were added so that
176 20,000 cells were deposited in each well (19). The plates were then re-incubated for
177 5 days. For each serum, the process was repeated twice by two different, trained
178 people. After 5 days, CPE was evaluated under light microscopy by two independent
179 persons. Serum dilutions showing CPE were considered as non-neutralizing
180 (negative), while those showing no CPE were considered neutralizing/positive. Virus
181 sero-neutralization titer was reported as the highest dilution of serum that neutralizes
182 CPE in 50% of the wells (NT₅₀). If results from the 2 duplicate plates were
183 discordant, these samples were processed again in a subsequent SNT session. For
184 all sera showing a NT₅₀>1:320, a second process was made using higher dilutions
185 (up to 1:20,480). Positive (NT₅₀=1:160, from the Belgian National Reference Centre)
186 and negative (saline) controls were inserted in each plate.

187

188 **Assessment of total anti-spike IgGs**

189 The DiaSorin LIAISON SARS-CoV-2 TrimericS IgG assay (DiaSorin, Stillwater,
190 USA), a chemiluminescent immunoassay using magnetic particles coated with
191 recombinant trimeric SARS-CoV-2 spike protein, was used for quantitative
192 determination of IgG antibodies in human serum samples. The assay was performed
193 on LIAISON XL analyzer (DiaSorin) according to the manufacturer's instructions.

194 **Data analysis**

195 All the analyses were carried out in R version 4.1.1. All codes and data to reproduce
196 the results are available at : https://github.com/tashkeev-alex/vaccination_study.

197 **Estimating the decay rates**

198 Decay rates of anti-Spike IgG and NT₅₀ were estimated as previously reported
199 (14)(20)(21), i.e. by using linear mixed model with censoring, implemented in *lme4* R
200 package (22). Considering the sampling timeline in this study, we preferred to model

201 the dependency of the response variables on the number of days post-vaccine by
202 using single-slope rate using the data starting from T2. Namely, the model is:

$$\ln_{ij} = \beta_0 + \alpha_{0i} + \beta_1 \ln_{ij} + \alpha_{1i} \ln_{ij}$$

203 where \ln_{ij} is log of anti-Spike IgG or negative log of NT50 for individual i at time
204 point j post-vaccine 2nd dose, β_0 is global intercept, α_{0i} is a patient-specific
205 adjustment to β_0 , β_1 is a fixed slope dedicated to capture the average decay rate
206 across individuals, \ln_{ij} is number of days post-vaccine 2nd dose for individual i at
207 time point j , and α_{1i} is a patient-specific adjustment to β_1 . Likelihood ratio test was
208 used to detect whether rates were different between naive and SARS-CoV-2
209 experienced individuals.

210 **Separating individuals with neutralizing versus non-neutralizing** 211 **antibodies by anti-S IgG**

212 Logistic regression of neutralizing status at the last time point (T4 at 6 months post-
213 vaccine, 1st dose) on the log of anti-Spike IgG was used to determine the threshold
214 immunoglobulin value that provides the best separation of the classes. Sensitivity
215 and specificity of the model were estimated by summarizing those across five
216 stratified folds of cross-validation (no hyperparameter tuning or model selection was
217 performed).

218 **Testing for differences or associations among immune and clinical** 219 **parameters**

220 In all corresponding procedures we used non-parametric statistics, i.e. either tie-
221 corrected Spearman correlation coefficient or Wilcoxon rank-sum test. We used log-
222 transformed anti-Spike IgG, NT50, and IFN- γ values. In multiple linear regression
223 models, we centered and scaled the continuous predictors by two standard
224 deviations allowing the comparison of coefficients for continuous and binary
225 predictors on the same scale (23). In case of continuous dependent variables, we
226 centered and scaled them in the same way. In case of multivariate dependent
227 variables (anti-S IgG or NT50 across time points), we centered and scaled them
228 across individuals within each time point.

229 **Results**

230 **Cohort characteristics, demographics and samples collection**

231 Our study included 208 consenting subjects among the CHU of Liège staff members
232 who received the Pfizer–BioNTech BNT162b2 vaccine during February 2021. Among
233 them, 158 were SARS-CoV-2 naïve subjects while 50 had COVID-19 prior to
234 vaccination (experienced SARS-CoV-2). The cohort was skewed toward females
235 (~80%). The age was however balanced between naïve (34-53 years old) and
236 experienced groups (37-55 years old) with median of 43 and 46 respectively. The
237 BMI was also balanced between the two groups with a median of 24,8 (21,3 to 27,7)
238 for naïve and 24,0 (21,4 to 27,3) for experienced. Comorbidities of the participants
239 included asthma (11% in naïve group and 6,2% in experienced group), autoimmunity
240 autoimmunity (5,3% in naïve group - 3 with Hashimoto's thyroiditis, 3 with
241 hypothyroidism, 2 with Chron's disease, 1 with psoriasis, 1 with diabetes and
242 rheumatoid arthritis, and 2,1% in experienced group - 2 with Lupus and 1 with
243 psoriatic arthritis), blood cancer (non-active, 2% in naïve group and 0% in
244 experienced group), other cancers (non-active, 3,9% in naïve group and 4,2% in
245 experienced group) and immunodeficiency (1,3% in naïve group and 2,1% in
246 experienced group (**Table 1**).

247 In total, 1024 samples were collected. Sampling was performed the day of 1st and 2nd
248 dose of the vaccine (T0 and T1), then 2 weeks, 4 weeks and 6 months after the 1st
249 dose (T2, T3 and T4). 73% of naïve participants donated blood at all time points
250 while 21% and 5,7% donated blood 4 and 3 times respectively. In the experienced
251 group, 82% of subjects donated blood at all time points while 10% and 8% donated 4
252 and 3 times respectively (**Table 1**).

253 **Dynamics of humoral response to SARS-CoV-2 mRNA vaccine** 254 **BNT162b2**

255 We assessed the level of circulating trimeric Spike IgG in plasma samples using
256 DiaSorin LIAISON SARS-CoV-2 TrimericS IgG assay. The level of anti-Spike
257 antibodies clearly discriminates naïve and experienced groups at T0 (day of the 1st
258 vaccine dose). Median across experienced subjects was equal to 91.5 BAU/ml (4.8-
259 772) confirming pre-exposition to the virus. The level of anti-Spike antibodies
260 increased rapidly after the 1st vaccine dose in both groups but with higher titer in the

261 experienced group over the naive one (497 BAU/ml in naive, 6630 BAU/ml in SARS-
262 CoV-2 experienced). The anti-Spike circulating antibodies levels reached their
263 maximum two weeks after the 2nd vaccine dose and start declining two weeks later.
264 This decrease continued over time between two and six months after the 1st vaccine
265 dose with a half-life of 55 days. The kinetics of anti-Spike antibodies production was
266 similar between the naive and experienced groups. The levels of produced
267 antibodies were however significantly higher in the experienced group over the naive
268 group at all time points (**Figure 1 A, B**).

269 To evaluate the quality of secreted antibodies, we measured neutralization capacities
270 at all time points and all subjects using previously reported protocols (19). More than
271 a half of SARS-CoV-2-experienced participants (26/50) showed a detectable
272 neutralization (mostly 1:20) at the day of the vaccine 1st dose administration (T0) in
273 contrast to subjects with no prior SARS-CoV-2 infection (naive group) (only 9/158)
274 (**Figure 1C, D**). Some of them with detectable neutralization could be either
275 undiagnosed SARS-CoV-2 experienced individuals, or show cross-reactivity due to
276 previous infections by other coronaviruses. One month after the 1st vaccine dose
277 (T1), median neutralization titer increased substantially to 1:640 in experienced
278 group, while no such an increase was observed in the vast majority (only in 63/158)
279 of the naive group. Two weeks after the 2nd vaccine dose (T3), almost everyone
280 developed a neutralizing ability, disregarding the previous diagnosed viral exposure.
281 Despite the SARS-CoV-2 experienced participants showing higher neutralization
282 capacity at all time points including those after full vaccination, the decay rate was
283 similar in both participants types, namely the half-life period of 45 days after the 2nd
284 dose (**Figure 1C, D**). Noteworthy, the neutralization capacity at the last time point (6
285 months after the 1st vaccine dose) has decreased to non-detectable level in some
286 individuals, mostly in those who also showed poor response to the 1st vaccine dose
287 (26/31 of naive and 3/3 of SARS-CoV-2 experienced) (**Figure 1C, D**).

288 In clinical practice, measuring antibodies neutralization capacities is complicated and
289 time consuming. Therefore, and since measuring anti-Spike IgG level is routinely
290 used, we modeled the ability to use anti-Spike antibodies levels to predict whether a
291 person still has some neutralization capacity at some reasonably far time point after
292 vaccination (6 months in the case of our study) (**Figure 1E, F**). Logistic regression
293 classifier allowed to separate individuals with no detectable neutralization at the last
294 time point and the others by the anti-Spike IgG at the last time point (sensitivity:

295 mean=94%, std=3%; specificity: mean=70%, std=14% across five stratified folds of
296 cross-validation). The decision value estimated on the whole dataset was 326
297 BAU/ml. Using anti-Spike IgG level at earlier time points did not allow the
298 classification (**Figure S1**).

299

300 **Association of BNT162b2-induced anti-SARS-CoV-2 neutralizing** 301 **antibodies with participants' clinical parameters**

302 Because of the variable level of the anti-Spike circulating antibodies' quantity and
303 quality between vaccinated (naive and experienced) subject, we assessed the
304 association of total antibodies as well as neutralizing status of individuals at the last
305 time point with a reasonable set of available clinical parameters such as sex,
306 smoking status, age, and body mass index (BMI) in a single model containing also
307 one of the parameters representing the anti-Spike IgG level (**Figure 2**). By the latter
308 we considered SARS-CoV-2 infection history based on participant's self-reporting
309 (**Figure 2A**), anti-Spike IgG level before vaccination (T0) (**Figure 2B**), after 2 doses
310 vaccination (T2) (**Figure 2C**), or 6 months after vaccination (T4) (**Figure 2D**). Among
311 all tested clinical parameters, only age was significantly associated with the
312 neutralizing status (decreasing chances to have neutralizing capacity), and even its
313 effect size was far less (1.4-5.3x) than that of the parameter representing anti-Spike
314 IgG level. No effect of sex, smoking status, and BMI were detected at any
315 significance level (**Figure 2**).

316

317 We next tested the association of humoral response parameters themselves with the
318 abovementioned set of clinical parameters across all time points (**Figure 3**). Since
319 NT50 and anti-Spike IgG levels were strongly correlated at each time point for both
320 SARS-CoV-2-experienced and naive individuals (**Figure 3A**), we tested them in
321 separate models using either multivariate (**Figure 3B, D**) or univariate (**Figure 3C, E**)
322 multiple linear regression, i.e. considering values across time points as a single
323 vector or separately. Again, only age showed a significant association with the
324 outcomes explaining 25% and 21% of conditional variance in multivariate models for
325 anti-Spike IgG level and NT50, respectively. Interestingly, effects of age in univariate
326 models were negative (i.e. decreases humoral response parameter value) at all time
327 points except the first one, at which the effect was significant but of the opposite sign.
328 One plausible hypothesis could be that older individuals are more likely to face cold

329 coronaviruses before, and thus are more likely to show some baseline humoral
330 response to SARS-CoV-2.

331 **Cellular immune response to SARS-CoV-2 mRNA vaccine** 332 **BNT162b2**

333 To evaluate T-cell specific immune response to BNT162b2 vaccine, heparinized
334 whole blood was stimulated with SARS-CoV-2 specific peptides contained in the
335 QuantiFERON-SARS-CoV-2 tubes designed to activate both CD4T and CD8T cells.
336 IFN- γ was then measured by CLIA. Since this assay was only commercially available
337 after we completed the collection of samples at T0 to T3, we only assayed cellular
338 immune response at the last time point (T4) (**Figure 4**). Cellular response was
339 evaluated on 80 participants with 63 in the naive group and 17 in the experienced
340 group. In terms of IFN- γ secretion, we did not observe any significant difference
341 between naive and experienced groups for none of the antigen used (Ag1 and Ag2)
342 (**Figure 4A, B**). However, when subjects were clustered based on their neutralizing
343 capacities at 6 months after vaccination, the difference was highly significant
344 between those with high neutralizing titers versus the one with no detectable
345 neutralization (**Figure 4B**). We next investigated if there was any association
346 between IFN- γ secretion, anti-Spike total antibodies and neutralizing antibodies titers.
347 As shown in figure 4A, there was no correlation between anti-S IgG and IFN- γ in the
348 naive group for both Ag1 and Ag2. Interestingly, IFN- γ secretion was highly
349 correlated to anti-Spike IgG in the experienced group (**Figure 4C top panel**). IFN- γ
350 secretion was also correlated to neutralization titers in all groups, although the
351 correlation was most significant in the experienced group for Ag1 ($p=3e-4$) over the
352 naive group ($p=0,0011$) and vice versa for Ag2 ($p= 0.0026$ for experienced and
353 $p=0,00029$ for naive) (**Figure 4C lower panel**). There was no statistically significant
354 association between cellular immune response parameters and any of the available
355 clinical parameters (**Figure S3**).

356

357 **COVID-19 testing of the study participants.**

358

359 Participants were all invited to perform a weekly saliva self-sampling to detect the
360 presence of SARS-CoV-2. Nevertheless, the adherence to the weekly SARS-CoV-2

361 sampling rapidly dropped down (**Figure S4**). Only one participant was tested as
362 positive during the study timeline.

363 Discussion

364 Our study confirms previous evidence for an earlier, stronger and more persistent
365 humoral immune response in individuals previously infected with SARS-CoV-2
366 versus naïve individuals following vaccination with the BNT162b2 mRNA vaccine
367 (24). The anti-spike antibody and neutralization capacity levels six months after
368 vaccination protocol were significantly higher in SARS-CoV-2 experienced HCWs
369 compared to naïve HCWs. We did not observe such differences regarding cellular
370 immune response six months following 2nd dose vaccination. Reassuringly, most
371 participants had a detectable cellular immune response to SARS-CoV-2 six months
372 after vaccination. These findings are in line with a recent observation from
373 Samanovic and colleagues who also reported more pronounced differences in
374 humoral, over cellular responses between individuals SARS-CoV-2-naive versus
375 recently SARS-CoV-2 experienced subjects (25).

376 Besides the impact of SARS-CoV-2 infection history on immune response to
377 BNT162b2 mRNA vaccine, we observed a significant association between age and
378 persistence of humoral response. The more elderly is a participant, the less durable
379 was the humoral response. This is in line with results from other studies
380 demonstrating a similar decrease of anti-SARS-CoV-2 antibodies in all age groups
381 few months after the second vaccine dose, especially among 65 years-old or older
382 persons (26). Regarding cellular immune response, although not statistically
383 significant, we observed a trend towards a negative impact of age.

384 Our results confirm previous findings indicating that anti-spike antibodies are very
385 well correlated with neutralizing antibodies (27)(28). This may allow to set a
386 threshold of anti-spike antibodies predicting neutralization capacity with a high
387 sensitivity. Although correlates of protection from SARS-CoV-2 are not fully defined
388 yet, Khoury and colleagues showed that neutralization level is highly predictive of
389 immune protection, reinforcing the results of other reports suggesting that
390 neutralization titer is an important predictor of vaccine efficacy (21)(29)(30). Our
391 findings may thus have important implications for waning vaccine immunity and
392 vaccination strategies. Our results may also contribute to better define patients who

393 are at high risk of developing severe COVID-19 and who could benefit from anti-
394 SARS-CoV-2 mAb products (PMID: 35016195) (PMID: 34087172). Available stocks
395 of mAbs that retained activity against Omicron are extremely limited in most settings,
396 while many vulnerable patients can be considered as eligible for this treatment.
397 Predictors of remaining neutralization capacity may help clinicians with the difficult
398 selection of patients for whom this intervention would be most beneficial.

399 The humoral immune response as measured through quantification of anti-spike IgG
400 or neutralizing antibodies correlated with cellular immune responses six months
401 following vaccination. Interestingly, this correlation was much stronger in the group of
402 participants with a history of SARS-CoV-2 infection, indicating that the level of anti-
403 spike antibodies in this group may not only predict the level of neutralizing antibody
404 but also the level of cellular immunity as well.

405 In conclusion, our data strongly reinforce the relevance of previous SARS-CoV-2
406 infection for understanding vaccine immune responses. It may have implications for
407 personalizing mRNA vaccination regimens used to prevent severe COVID-19 and
408 reduce the impact of the pandemic on the healthcare system. More specifically, it
409 may help prioritizing vaccination, including for the deployment of booster doses.

410

411 **Author Contributions:** “Conceptualization: DD, SR, GD; methodology: DD, SR, GD;
412 formal analysis: SD, AT, DD, SR, GD; investigation: SD, AT, NM, HP, YT, LL, CF,
413 BP, CL, MW, MM, NF, LL, MPH; writing-original draft preparation, SD, AT, DD, SR,
414 GD; review and editing: all authors; supervision: LG, FB, SR, MPH, MM, CM, GD,
415 DD; funding acquisition: GD, SR, MM. All authors have read and agreed to the
416 published version of the manuscript.”

417 **Funding:** Léon Fredericq Foundation (To GD and MM), FNRS (Fonds National de la
418 Recherche Scientifique) (To SR, grant N° PER/PGY H.P030.20)). AT is aspirant
419 FNRS (PhD fellow), GD is an FNRS postdoctoral clinical master specialist and SR is
420 an FNRS Senior Research Associate. The funders had no role in study design, data
421 collection and analysis, decision to publish, or preparation of the manuscript.

422 **Institutional Review Board Statement:** The study was conducted according to the
423 guidelines of the Declaration of Helsinki, and approved by the Ethical Committee
424 (comité d'éthique hospitalo-facultaire universitaire de Liège, approval number 2021-
425 54).

426 **Informed Consent Statement:** Informed consent was obtained from all subjects
427 involved in the study

428 **Data Availability Statement:** Data is contained within the article or supplementary
429 material

430 **Acknowledgments:** We are very thankful to all HCW participants in this study. We
431 are also very thankful to Jean-Baptiste Giot, Frederic Fripiat, Anne-Sophie
432 Sauvage, Philippe Leonard, Raphaël Schils, Sébastien Bontemps, Cecile Meex and
433 Margaux Dandoy for clinical assistance and scientific helpful discussions.


434 **Conflicts of interest:** FB and LG are the inventors of the device used in the saliva
435 collection kit. This device was patented (EP20186086.3) and produced by Diagenode
436 (Seraing, Belgium) under a commercial agreement with the University of Liège. This
437 does not alter the adherence to all journal policies on sharing data and materials. The
438 rest of the authors have no competing interests to declare.

439

Table 1. Cohort description

Characteristic	naive, N = 158[†]	recovered, N = 50[†]
Sex		
F	125 (80%)	39 (80%)
M	31 (20%)	10 (20%)
Unknown	2	1
Age		
	43 (34, 53)	46 (37, 55)
Unknown	2	1
Smoking		
	25 (16%)	5 (10%)
Unknown	2	1
BMI		
	24.8 (21.3, 27.7)	24.0 (21.4, 27.3)
Unknown	8	2
Asthma		
	17 (11%)	3 (6.2%)
Unknown	5	2
Autoimmunity		
	8 (5.3%)	1 (2.1%)
Unknown	6	2
Immunodeficiency		
	2 (1.3%)	1 (2.1%)
Unknown	7	2
Blood Cancer		
	3 (2.0%)	0 (0%)
Unknown	5	2
Other Cancer		
	6 (3.9%)	2 (4.2%)
Unknown	5	2
# time points		
3	9 (5.7%)	4 (8.0%)
4	33 (21%)	5 (10%)
5	116 (73%)	41 (82%)
[†] n (%); Median (IQR)		

441 **Figures**



442

Figure 1

443


444 **Figure 1. Dynamics of humoral immune response to SARS-CoV-2 mRNA**
 445 **vaccine BNT162b2. (A-B) dynamics of anti-Spike IgG (\log_{10} BAU/ml) – median**
 446 **across individuals per approximate time point (A), or for each individual (B) with**
 447 **exact time points; (C-D) dynamics of virus neutralization titer ($-\log_{10}$ values, zeroed if**

448 *titer was above 1/20*) – median across individuals per approximate time point (C), or
449 for each individual with exact time points (D); **(E)** same as in **(A)**, but grouping
450 individuals by the ability to neutralize virus at the last time point (*based on (C)*); **(F)**
451 Logistic regression-derived boundary value of anti-Spike IgG level at the last time
452 point separating individuals with no detectable neutralization at the last time point
453 from the others (*inability to separate them by anti-Spike IgG at earlier time points is*
454 *shown on S1 Fig*), mean \pm standard deviation values of the model performance are
455 shown.

456

457

Figure 2




458

459 **Figure 2.** Effects of clinical parameters on neutralizing status at six months after 1st
460 vaccination dose. given the (A) experience status, (B) anti-Spike IgG level at 1st time
461 point (*T0* : day of the 1st vaccine dose), (C) anti-Spike IgG level at T2 time point
462 (*after 2nd vaccine dose*), or (D) anti-Spike IgG level at T4 (*6 months after*
463 *vaccination*). Regression coefficients for all predictors can be compared on the same
464 scale since continuous predictors were centered and scaled by two standard
465 deviations

466

467


Figure 3



468 **Figure 3. Associations between humoral immune response and clinical**
469 **parameters across time points. (A)** Spearman correlation (ρ) between
470 neutralization titer and level of anti-Spike IgG for each time point (*T1-T5*); **(B)** Effects
471 of clinical parameters on level of anti-Spike IgG across time points in a multivariate
472 multiple regression model (*left*), or in a univariate multiple regression model per time
473 point (*right*); **(C)** Same as (B) but for NT50 instead of anti-Spike IgG level.
474

475

Figure 4



476 **Figure 4. Associations between cellular and humoral responses in naïve versus**
477 **SARS-CoV-2 experienced groups. (A)** Comparison of cellular immune response
478 (QuantiFERON-SARS-CoV-2 Ag1 (left panel) and QuantiFERON-SARS-CoV-2 Ag2
479 (right panel) between SARS-CoV-2 experienced (orange) and naïve (blue) groups.
480 **(B)** Same as (A) but comparing individuals with no detectable neutralization at the 6
481 months after 1st vaccine dose (yellow) and those with neutralizing titers (blue) at the
482 same time point. **(C)** Spearman correlation (ρ) between anti-Spike IgG level (top
483 panels) or neutralization titer (bottom panels) with cellular response represented by
484 QuantiFERON-SARS-CoV-2 Ag1 (left) or Ag2 (right).

485

486

Supplementary information

487

488 **Kinetics and persistence of the cellular and humoral immune**
489 **responses to BNT162b2 mRNA vaccine in SARS-CoV-2-naive and -**
490 **experienced subjects**

491

492 Salome Desmecht^{1,2¶}, Aleksandr Tashkeev^{1¶}, Nicole Marechal³, H el ene Per ee¹,
493 Yumie Tokunaga¹, Celine Fombellida Lopez^{2,3}, Barbara Polese⁴, C eline Legrand⁴,
494 Marie W ery¹, Myriam Mni¹, Nicolas Fouillien¹, Fran oise Toussaint⁷, Laurent Gillet⁵,
495 Fabrice Bureau⁴, Laurence Lutteri⁶, Marie-Pierre Hayette⁷, Michel Moutschen^{2,3},
496 Christelle Meuris³, Daniel Desmecht^{8&}, Souad Rahmouni^{1&}, Gilles Darcis^{2,3&}

497

498


499

500

Supplementary figures

501

502



503


504 **Figure S1:** Inability to separate individuals neutralizing and non-neutralizing at last

505 time point by anti-Spike IgG values at earlier time points. G-mean is a geometric

506 mean of sensitivity and specificity, a single metric used to evaluate the model.

507

508




509

510 **Figure S2:** Absence of impact of time after recovery on humoral response

511 parameters before and after 1st vaccine dose.

512

513




514

515 **Figure S3:** Effects of clinical parameters on cellular response at the last time point.

516

517
518



519

520 **Figure S4:** Statistics of COVID-19 testing of the study participants. Only one
521 participant was tested as positive during the study timeline.

522

523 **References**

- 524 1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and
525 Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N. Engl. J. Med.* 2020;
- 526 2. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and
527 Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N. Engl. J. Med.* 2021;
- 528 3. Reis BY, Barda N, Leshchinsky M, Kepten E, Hernán MA, Lipsitch M, et al.
529 Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents. *N. Engl. J.*
530 *Med.* 2021;
- 531 4. Ali K, Berman G, Zhou H, Deng W, Faughnan V, Coronado-Voges M, et al. Evaluation
532 of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents. *N. Engl. J. Med.* 2021;
- 533 5. Walter EB, Talaat KR, Sabharwal C, Gurtman A, Lockhart S, Paulsen GC, et al.
534 Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. *N.*
535 *Engl. J. Med.* 2021;
- 536 6. Meuris C, Kremer C, Geerinck A, Locquet M, Bruyère O, Defêche J, et al.
537 Transmission of SARS-CoV-2 after COVID-19 Screening and Mitigation Measures for
538 Primary School Children Attending School in Liège, Belgium. *JAMA Netw. Open.*
539 2021;
- 540 7. Darcis G, Meuris C, Kremer C, Faes C, Hens N. The Risk of Underestimating the
541 Contribution of Children to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-
542 CoV-2) Pandemic. *Clin. Infect. Dis.* 2021;
- 543 8. Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas EJ, et al.
544 Waning Immunity after the BNT162b2 Vaccine in Israel. *N. Engl. J. Med.* 2021;
- 545 9. Chemaitelly H, Tang P, Hasan MR, AIMukdad S, Yassine HM, Benslimane FM, et al.
546 Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. *N.*
547 *Engl. J. Med.* 2021;
- 548 10. Rosenberg ES, Dorabawila V, Easton D, Bauer UE, Kumar J, Hoen R, et al. Covid-19
549 Vaccine Effectiveness in New York State. *N. Engl. J. Med.* 2021;
- 550 11. Bruxvoort KJ, Sy LS, Qian L, Ackerson BK, Luo Y, Lee GS, et al. Effectiveness of
551 mRNA-1273 against Delta, Mu, and other emerging variants. *medRxiv.* 2021;

- 552 12. Collier AY, Yu J, McMahan K, Liu J, Chandrashekar A, Maron JS, et al. Differential
553 Kinetics of Immune Responses Elicited by Covid-19 Vaccines. *N. Engl. J. Med.* 2021;
- 554 13. Guerrera G, Picozza M, D'Orso S, Placido R, Pirronello M, Verdiani A, et al.
555 BNT162b2 vaccination induces durable SARS-CoV-2-specific T cells with a stem cell
556 memory phenotype. *Sci. Immunol.* 2021;
- 557 14. Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, et al. mRNA vaccines
558 induce durable immune memory to SARS-CoV-2 and variants of concern. *Science*
559 (80-). 2021;
- 560 15. Uriu K, Kimura I, Shirakawa K, Takaori-Kondo A, Nakada T, Kaneda A, et al.
561 Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum.
562 *N. Engl. J. Med.* 2021;
- 563 16. Garcia-Beltran WF, St. Denis KJ, Hoelzemer A, Lam EC, Nitido AD, Sheehan ML, et
564 al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against
565 SARS-CoV-2 Omicron variant. *Cell* [Internet]. 2022; Available from:
566 <https://linkinghub.elsevier.com/retrieve/pii/S0092867421014963>
- 567 17. Muhsen K, Maimon N, Mizrahi A, Varticovschi B, Bodenheimer O, Gelbshtein U, et al.
568 Effects of BNT162b2 Covid-19 Vaccine Booster in Long-Term Care Facilities in Israel.
569 *N. Engl. J. Med.* [Internet]. 2021; Available from:
570 <http://www.nejm.org/doi/10.1056/NEJMc2117385>
- 571 18. Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, et al. Effectiveness
572 of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe
573 outcomes in Israel: an observational study. *Lancet.* 2021;
- 574 19. Wu HS, Chiu SC, Tseng TC, Lin SF, Lin JH, Hsu YF, et al. Serologic and Molecular
575 Biologic Methods for SARS-associated Coronavirus Infection, Taiwan. *Emerg. Infect.*
576 *Dis.* 2004;
- 577 20. Wheatley AK, Juno JA, Wang JJ, Selva KJ, Reynaldi A, Tan HX, et al. Evolution of
578 immune responses to SARS-CoV-2 in mild-moderate COVID-19. *Nat. Commun.* 2021;
- 579 21. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al.
580 Neutralizing antibody levels are highly predictive of immune protection from
581 symptomatic SARS-CoV-2 infection. *Nat. Med.* 2021;

- 582 22. Vaida F, Liu L. Fast implementation for normal mixed effects models with censored
583 response. *J. Comput. Graph. Stat.* 2009;
- 584 23. Gelman A. Scaling regression inputs by dividing by two standard deviations. *Stat.*
585 *Med.* 2008;
- 586 24. Ontañón J, Blas J, de Cabo C, Santos C, Ruiz-Escribano E, García A, et al. Influence
587 of past infection with SARS-CoV-2 on the response to the BNT162b2 mRNA vaccine
588 in health care workers: Kinetics and durability of the humoral immune response.
589 *EBioMedicine.* 2021;
- 590 25. Samanovic MI, Cornelius AR, Gray-Gaillard SL, Allen JR, Karmacharya T, Wilson JP,
591 et al. Robust immune responses are observed after one dose of BNT162b2 mRNA
592 vaccine dose in SARS-CoV-2 experienced individuals. *Sci. Transl. Med.* [Internet].
593 2021;eabi8961. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/34874183>
- 594 26. Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning Immune
595 Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. *N. Engl. J. Med.*
596 2021;
- 597 27. Saadat S, Rikhtegaran Tehrani Z, Logue J, Newman M, Frieman MB, Harris AD, et al.
598 Binding and Neutralization Antibody Titers after a Single Vaccine Dose in Health Care
599 Workers Previously Infected with SARS-CoV-2. *JAMA - J. Am. Med. Assoc.* 2021;
- 600 28. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory
601 to SARS-CoV-2 assessed for up to 8 months after infection. *Science (80-.).* 2021;
- 602 29. Addetia A, Crawford KHD, Dingens A, Zhu H, Roychoudhury P, Huang ML, et al.
603 Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a
604 fishery vessel outbreak with a high attack rate. *J. Clin. Microbiol.* 2020;
- 605 30. Lumley SF, O'Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, et al.
606 Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. *N.*
607 *Engl. J. Med.* 2021;
- 608
- 609